Leading diagnostics companies join forces to establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)

WASHINGTON , Nov. 17, 2020 /PRNewswire/ -- Seven leading diagnostics companies and laboratory service providers have formed the Access to Comprehensive Genomic Profiling Coalition (ACGP). The goal of the organization is to collectively advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer. The current members of ACGP are Exact Sciences (NASDAQ: EXAS), Foundation Medicine, Illumina (NASDAQ: ILMN), LabCorp (NYSE: LH), QIAGEN (NYSE: QGEN), Roche Diagnostics (SIX: RO, ROG: OTCQX: RHHBY), and Thermo Fisher Scientific (NYSE: TMO).

LabCorp is scheduled to present at the 29th annual Credit Suisse virtual healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 2, 2020-- LabCorp (NYSE: LH) today announced that members of the executive management team will participate in a virtual fireside chat at the 29 th Annual Credit Suisse Virtual Healthcare Conference on Monday, Nov. 9 at 8:00 a.m. ET .

LabCorp and BML of Japan expand development and commercialization agreement for precision medicine in Japan

BURLINGTON, N.C., and TOKYO, Nov. 1, 2020 — LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and BML, a leading Japanese provider of clinical laboratory testing services, announced an expanded agreement to provide development and delivery of companion diagnostics in Japan.

Labcorp and University Of Miami health system enter laboratory service agreement

LabCorp announces 2020 third quarter results

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 27, 2020-- LabCorp (or the Company) (NYSE: LH) today announced results for the third quarter ended September 30, 2020.

LabCorp transforms the clinical trial experience and streamlines the drug development process

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 20, 2020-- LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced new capabilities that will transform the clinical trial experience with the goal of streamlining the drug development process. This transformation will enable LabCorp’s drug development business, Covance, a global leader in decentralized clinical trials (DCTs), to quickly and efficiently connect patients to clinical trials, which will allow for better access to potential drugs, vaccines, and medical devices. Additionally, the seamless, tech-enabled, patient-centric capabilities will provide a better clinical trial experience for patients, and biopharmaceutical and medical device customers.

LabCorp and Swedish extend laboratory services relationship, providing continued access to high-quality diagnostics and COVID-19 testing

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 19, 2020-- LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and Swedish, the largest nonprofit healthcare system in the Puget Sound region, today announced an agreement to extend their more than 20-year relationship.